

Pharmacy Grand Rounds

200 First Street SW Rochester, Minnesota 55905 https://ce.mayo.edu/pharmacy-grandrounds-2025

Beyond Injections: Orforglipron and the Future of Oral GLP-1 Therapy

Session Date: 09/23/2025

Session Time: 11:00 – 11:45 AM (CST)

Target Audience

This continuing education (CE) session was planned to meet the needs of professional staff who deal with the selection and monitoring of medication(s) as part of their patient care duties, including pharmacists, RNs, APRNs, PAs, MDs.

Activity Overview

The American Diabetes Association 2025 Standards of Care in Diabetes recommends GLP-1 RAs (glucagon-like peptide-1 receptor agonists) as a preferred option for treatment of type II diabetes, specifically in patients who have established or are at high risk for atherosclerotic cardiovascular disease (ASCVD), as well as patients desiring weight loss. Historically, injectable formulations of GLP-1 RAs have shown greater efficacy for treatment of type II diabetes and weight loss compared to the only oral formulation currently on the market, oral semaglutide. However, injectable medications come with their own challenges, such as discomfort upon administration, incorrect administration technique, storage restrictions, and high cost. This presentation will primarily focus on the literature regarding the novel, oral GLP-1 RA, orforglipron, and its efficacy for treating type II diabetes, inducing weight loss, and improving cardiovascular risk biomarkers. In addition to orforglipron, literature on currently FDA-approved GLP-1 RAs and Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 RAs will be discussed.

Learning Objectives

At the conclusion of this knowledge-based CE session, participants should be able to:

- 1. Discuss the current guideline recommendations for the use of GLP-1 RAs for type II diabetes, weight loss, and ASCVD risk reduction.
- 2. Explain the unique structure of orforglipron and its impact on drug administration.
- 3. Compare the efficacy of orforglipron to other GLP-1 RAs and GIP/GLP-1 RAs through literature analysis.

Faculty Information

Jessica Roberts, PharmD PGY2 Ambulatory Care Pharmacy Resident Mayo Clinic Hospital - Rochester, MN

Jessica received a Doctor of Pharmacy degree from Drake University College of Pharmacy and is a current a PGY2 ambulatory care pharmacy resident at Mayo Clinic Hospital – Rochester. Her practice interests include primary care, infectious diseases, and autoimmune disorders.



Approved Provider Statement



In support of improving patient care, this activity is planned and implemented by Mayo Clinic College of Medicine and Science. Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statements

AMA

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE



ACPE Universal Activity Number (UAN): JA0000238-0000-25-035-L01-P Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 0.75 ACPE Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity

ANCC

Mayo Clinic College of Medicine and Science designates this activity for a maximum of 0.75 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

AAPA



Mayo Clinic College of Medicine and Science has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Educational Format and CE Requirements

This CE session is available as a live presentation, including live webcast. Participants must complete the following to record attendance and obtain CE credit:

- 1. Attend the entire session.
- 2. Text the session code to 507-200-3010 within 48 hours of the live presentation to record attendance.
 - a. This number is only used for receiving text messages related to tracking attendance
 - b. Employees are encouraged to create a contact in their mobile phone, as the same number is used to record attendance for every session
- 3. Complete the online evaluation for the respective session within 2 weeks of live presentation.

Pharmacist CE credit is electronically transferred to the National Association of Boards of Pharmacy CPE Monitor. To track CE, please go to NABP CPE Monitor.

Non-pharmacist attendees can print out a record of attendance at ce.mayo.edu after completing the evaluation and claiming credit.

Live Webcast – Register from the Education SharePoint site

Disclosure Summary

As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. All who are in a position to control the content are required to disclose all financial relationships with any ineligible company. Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed:

The faculty report the following relationships:

- Jessica Roberts, PharmD
 - o Declares no financial relationship(s) pertinent to this session
 - O Declares off-label use of medication(s) will be discussed during this presentation for the following medication(s):
 - Orforglipron Eli Lilly and Company

Course Director and Planning Committee Members declare the following relevant financial relationship(s) pertinent to this session.

- No relevant financial relationship(s) with ineligible companies:
 - o Jennifer Elmer, DNP, APRN, CCNS
 - o Andrew Herber, PA-C
 - Sarah Jane Kotval, BSW, RSS Coordinator

- Scott Nei, PharmD, BCPS, BCCCP, FCCM, FMSHP
- o Sara Thompson, PharmD, MEd, BCACP
- Relevant financial relationship(s) with ineligible companies:
 - o Wayne Nicholson, MD, PharmD, BCPS Intellectual Property Anivive Lifesciences, Inc.

All relevant financial relationships have been mitigated.

For additional disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee members visit ce.mayo.edu, About Us, Disclosures - or - https://ce.mayo.edu/content/disclosures

System and Technical Requirements

For participants viewing the webcast, sessions are delivered via Mayo Clinic intranet web browser and Adobe® PDF. For participants viewing outside the Mayo Clinic firewall, a VPN connection is required for remote access. Recommended web browser includes Google Chrome. This session is planned and coordinated by the **Department of Pharmacy, Mayo Clinic.**